FDA lifts hold on one of two Phase 3 gene editing studies by Intellianews2026-01-27T15:52:33+00:00January 27th, 2026|Endpoints News|
Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharmanews2026-01-27T15:40:01+00:00January 27th, 2026|Endpoints News|
AstraZeneca ends work on cardio drug; Lisata and Qilu terminate dealnews2026-01-27T14:31:24+00:00January 27th, 2026|Endpoints News|
Virtual women’s health company Wisp buys TBD Healthnews2026-01-27T14:00:56+00:00January 27th, 2026|Endpoints News|
Boehringer Ingelheim gets an IBD bispecific from Shanghai-based Simcerenews2026-01-27T13:56:41+00:00January 27th, 2026|Endpoints News|
FDA greenlights Life Biosciences’ gene therapy study to rewind the age of cellsnews2026-01-27T13:00:47+00:00January 27th, 2026|Endpoints News|
Updated: Roche’s obesity shot posts decent weight loss in mid-stage test, heads to Phase 3news2026-01-27T12:09:37+00:00January 27th, 2026|Endpoints News|
TRexBio gets another $50M to bring more Treg candidates into the clinicnews2026-01-27T12:00:48+00:00January 27th, 2026|Endpoints News|
UK-US biotech investor Epidarex raises $145M for fourth fundnews2026-01-27T07:00:57+00:00January 27th, 2026|Endpoints News|
IRA drug pricing petitions pile up at the Supreme Court news2026-01-26T20:21:13+00:00January 26th, 2026|Endpoints News|
